S. Chapman

发表

Clinical potential of a new HIV protease inhibitor.

M. Youle, M Youle, S Chapman, 1995, Journal of the International Association of Physicians in AIDS Care.

Safety, Pharmacokinetics, and Antiretroviral Activity of the Potent, Specific Human Immunodeficiency Virus Protease Inhibitor Nelfinavir: Results of a Phase I/II Trial and Extended Follow‐up in Patients Infected with Human Immunodeficiency Virus

M. Youle, G. Moyle, W. Prince, 1998, Journal of clinical pharmacology.

Effect of acyclovir on radiation- and chemotherapy-induced mouth lesions

C. Crumpacker, G. Bubley, L. Schnipper, 1989, Antimicrobial Agents and Chemotherapy.

Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511)

M. Saag, P. Tebas, M. Conant, 2001, AIDS.

Oral acyclovir in the treatment of acute herpes zoster ophthalmicus.

T. Liesegang, J. Sutphin, G. Foulks, 1986, Ophthalmology.

Oral acyclovir for episodic treatment of recurrent genital herpes. Efficacy and safety.

L. Goldberg, R. Kaufman, M. Conant, 1986, Journal of the American Academy of Dermatology.

Transverse Leukonychia in Patients Receiving Cancer Chemotherapy

Philip R. Cohen, S. Chapman, 1997, Southern medical journal.

Oral acyclovir in the therapy of acute herpes zoster ophthalmicus. An interim report.

T. Liesegang, J. Sutphin, G. Foulks, 1985, Ophthalmology.

Efficacy of desciclovir in the treatment of Epstein-Barr virus infection in oral hairy leukoplakia.

E. Lennette, J. Greenspan, H. Hollander, 1990, Journal of acquired immune deficiency syndromes.

Long-term response of recurrent respiratory papillomatosis to treatment with lymphoblastoid interferon alfa-n1

H. Kashima, P. Mounts, S. Buckley, 1991 .

Pharmacokinetics of acyclovir suspension in infants and children

M. Levin, J. Connor, S. Weller, 1987, Antimicrobial Agents and Chemotherapy.

Predictors of optimal virological response to potent antiretroviral therapy.

M. Saag, W. Powderly, N. Clendeninn, 1999, AIDS.

A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection.

D. Ho, A. Hurley, M. Markowitz, 1998, The Journal of infectious diseases.

Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir

D. R. Kuritzkes, Y. Cao, D. Kuritzkes, 1998, Antimicrobial Agents and Chemotherapy.

Long-term response of recurrent respiratory papillomatosis to treatment with lymphoblastoid interferon alfa-N1. Papilloma Study Group.

H. Kashima, P. Mounts, S. Buckley, 1991, New England Journal of Medicine.

Pharmacokinetics ofAcyclovir Suspension inInfants andChildren

W. Dankner, S. Chapman, R. Straube, 1987 .

Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study.

S. Jones, S. Chapman, A. Opaneye, 1997, Genitourinary medicine.